Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Holling Bio-Pharma Corporation
Entity

Holling Bio-Pharma Corporation

Tracked across 1 events · 6 articles · First seen Aug 07, 2026 · Last active Aug 07, 2026

Sentiment
35
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
2 35
Business
Nxera Pharma Q2 2026 Results
Nxera Pharma reported its consolidated results for the second quarter ended 30 June 2026, showing a significant improvement in financial performance. Revenue increased to JPY 18,910 million (US$119.6 million), up from JPY 15,095 million in…
Impact: Holling received marketing approval from the Taiwan FDA for QUVIVIQ, enabling commercialization of the insomnia treatment in Taiwan.
Aug 07, 2026 · 6 articles
Key Actions (1)
70 Holling Bio-Pharma Corporation received marketing approval United States — Food and Drug AdministrationNxera Pharma Q2 2026 Results
ERGEN INTELLIGENCE
Track Holling Bio-Pharma Corporation live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.